Company environment · Antibody-drug conjugates · Korea MFDS
A cancer drug’s first approval in Korea
Just approved in Korea; preparing launch. Start at the top to see what the company does, then the jobs AI models were given here and how each scored.
1What does this company do?
The Korean branch of a global drug company.
It handles the Korean approval and launch of a drug already approved elsewhere — and the Korean file must stand on what was known there on approval day.
For experts
Korean affiliate of a global sponsor at first local marketing approval — an approval-day file and a next-morning launch handoff.
2Where is the product on its way to patients?
An antibody that carries chemotherapy into cancer cells, just approved in Korea for the first time.
- 1Discovery
- 2Lab & animal studies
- 3Human trials
- 4Filing & review
- 5Approved
- The product is here
- 6On the market
The branch must close out the approval file and hand over to launch, using only what was known on that date.
For experts
Antibody-drug conjugate newly approved in Korea; jobs verify colleagues’ “assembled” packs and close out the designation, labeling, and post-approval commitment files.
3What is happening right now?
The day of first approval; the launch handoff is tomorrow.
Colleagues say several packs are “assembled”. Each job checks whether they really are.
4Which jobs were the models given?
7 jobs, each graded against a specialist’s checklist.
Scores are checks passed out of checks in the list. Each model ran each job once.
This company’s files stay private.
The jobs on this page are scored as part of the official 71-task benchmark. The files, the model’s steps, and each check stay unpublished, because they come from a real product’s records. To follow a job all the way down, open one of our open companion showcases (evaluated separately from the benchmark totals).
Havenor Therapeutics (fictional showcase) →
Broad Institute (public FDA record showcase) →